ESMO China Voice | Prof. Jian Zhang: SMP-656 Shows Early Promise, Offering New Hope for Patients Resistant to HER2 ADC Therapy
Editor’s Note: With its remarkable therapeutic efficacy, DS-8201 has dramatically reshaped the treatment landscape for patients with advanced breast cancer. In HER2-positive advanced breast cancer, DS-8201 has firmly established its…









